Therapeutic Agents That Inhibit Angiogenesis

[1]  S. Teo.  Properties of thalidomide and its analogues: Implications for anticancer therapy , 2005, The AAPS Journal.

[2]  G. Gasparini,et al.  Challenges of antiangiogenic therapy of tumors , 2008 .

[3]  T. Overbeck,et al.  Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) , 2007 .

[4]  W. Rathmell,et al.  Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[5]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[6]  A. Verkleij,et al.  Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies , 2007, Cancer Immunology, Immunotherapy.

[7]  C. Tournigand,et al.  Targeted agents for adjuvant therapy of colon cancer. , 2006, Seminars in oncology.

[8]  J. Desai,et al.  Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors , 2006, Annals of Internal Medicine.

[9]  R. Herbst.  Therapeutic options to target angiogenesis in human malignancies , 2006, Expert opinion on emerging drugs.

[10]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[11]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Ratain,et al.  Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.

[13]  G. Semenza,et al.  Regulation of angiogenesis by hypoxia-inducible factor 1. , 2006, Critical reviews in oncology/hematology.

[14]  R. Jain,et al.  The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.

[15]  E. Vokes,et al.  A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer , 2006 .

[16]  R. Bukowski,et al.  Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival , 2006 .

[17]  P. Bycott,et al.  A phase I study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Gauler,et al.  Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Herbst,et al.  A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  U. Gatzemeier,et al.  Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  F. D. De Braud,et al.  A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. O'Dorisio,et al.  An open-label phase II study evaluating the safety and efficacy of PTK787 in patients with progressive metastatic neuroendocrine cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Hart,et al.  A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Dudek,et al.  Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Kerr,et al.  A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Gladish,et al.  Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Mehta,et al.  Weekly carboplatin and nab-paclitaxel plus trastuzumab, or plus or minus bevacizumab: Clinical response in patients with breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Schlumberger,et al.  A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Herbst,et al.  Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): A subset analysis from a phase 1 dose-finding study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Sikic,et al.  A phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Figlin,et al.  Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Ryan,et al.  Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  W. Rathmell,et al.  Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Van Cutsem,et al.  Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Socinski,et al.  Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Bukowski,et al.  Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Hainsworth,et al.  Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  H. Wakelee,et al.  A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. Motzer,et al.  Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.

[40]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Kerbel.  Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer? , 2006, Science.

[42]  Alona Muzikansky,et al.  Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  P. Marynen,et al.  Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate , 2006, Clinical Cancer Research.

[44]  K. Bauer,et al.  Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Heymach,et al.  Emerging antiangiogenic agents in lung cancer. , 2006, Clinical lung cancer.

[46]  J. Doroshow,et al.  A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases , 2006, Clinical Cancer Research.

[47]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Allan H Friedman,et al.  Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Dachman,et al.  Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  I. Fidler,et al.  Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice , 2005, The Prostate.

[52]  Amanda J. Thomas,et al.  A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer , 2005, Journal of pediatric hematology/oncology.

[53]  J. Hainsworth,et al.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  B. Teicher,et al.  Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. , 2005, Cancer research.

[55]  Anil K Sood,et al.  Vascular Endothelial Growth Factor Trap Combined with Paclitaxel Strikingly Inhibits Tumor and Ascites, Prolonging Survival in a Human Ovarian Cancer Model , 2005, Clinical Cancer Research.

[56]  L. Saltz,et al.  Antibody-based therapies for colorectal cancer. , 2005, The oncologist.

[57]  D. Strumberg,et al.  Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. , 2005, Clinical colorectal cancer.

[58]  Z. Werb,et al.  PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival , 2005, Nature Cell Biology.

[59]  Qinghua Zhou,et al.  [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. , 2005, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[60]  William Pao,et al.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[61]  H. Groen,et al.  Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  H. Hurwitz,et al.  Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  C. V. D. van de Velde,et al.  Optimal locoregional treatment in gastric cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  R. Gray,et al.  O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599 , 2005 .

[65]  R. Govindan,et al.  O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study , 2005 .

[66]  Eric Masson,et al.  Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  R. Herbst,et al.  Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors , 2005 .

[68]  M. Prados,et al.  A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients , 2005 .

[69]  R. Bukowski,et al.  Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .

[70]  C. Fuchs,et al.  A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs) , 2005 .

[71]  J. Hainsworth,et al.  A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) , 2005 .

[72]  C. Takimoto,et al.  AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: Preliminary phase 1 results , 2005 .

[73]  R. Motzer,et al.  AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) , 2005 .

[74]  J. Hainsworth,et al.  Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial , 2005 .

[75]  R. Gray,et al.  Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 , 2005 .

[76]  J. Baselga,et al.  Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen , 2005 .

[77]  E. Borden,et al.  A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors , 2005, Molecular Cancer Therapeutics.

[78]  Jürgen Hennig,et al.  Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. , 2005, European journal of cancer.

[79]  M. Piccart,et al.  Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours , 2005, British Journal of Cancer.

[80]  Catherine Wheeler,et al.  A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer , 2005, Clinical Cancer Research.

[81]  Edward S. Kim,et al.  Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  E. Pedrinis,et al.  Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  G. Jayson,et al.  Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. , 2005, European journal of cancer.

[84]  B. Teicher,et al.  Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions , 2005 .

[85]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  L. Hlatky,et al.  Endostatin: the logic of antiangiogenic therapy. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[87]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[89]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[90]  F. Giancotti,et al.  Integrin β4 signaling promotes tumor angiogenesis , 2004 .

[91]  D. Strumberg,et al.  Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. , 2004, International journal of clinical pharmacology and therapeutics.

[92]  R. Herbst,et al.  151 AMG 706 first in human, open-label, dose-finding study evaluating the safety and pharmacokinetics (PK) in subjects with advanced solid tumors , 2004 .

[93]  A. Östman.  PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma , 2004 .

[94]  L. Schwartz,et al.  Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies , 2004 .

[95]  E. Vokes,et al.  Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) , 2004 .

[96]  R. Herbst,et al.  Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors , 2004 .

[97]  L. Norton,et al.  Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  H. Hurwitz,et al.  Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  J. Hainsworth,et al.  Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  J. Mestan,et al.  AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. , 2004, Cancer research.

[101]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[102]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  R. Schilsky,et al.  Cancer and Leukemia Group B 90206 , 2004, Clinical Cancer Research.

[104]  J. Marshall,et al.  A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer , 2004, Clinical Cancer Research.

[105]  I. Bauerfeind,et al.  Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients , 2004, Clinical Cancer Research.

[106]  D. Heo,et al.  The effect of nitric oxide on cyclooxygenase‐2 (COX‐2) overexpression in head and neck cancer cell lines , 2003, International journal of cancer.

[107]  M. Heinrich,et al.  An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[108]  F. Rastinejad,et al.  Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. , 2003, Cancer research.

[109]  C. Betsholtz,et al.  Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. , 2003, The Journal of clinical investigation.

[110]  A. Klein-Szanto,et al.  CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. , 2003, Cancer research.

[111]  Edward S. Kim,et al.  977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer , 2003 .

[112]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[113]  R. Groszmann,et al.  Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. , 2003, Cancer cell.

[114]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[115]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[116]  T. Ng,et al.  A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[117]  G. Fontanini,et al.  Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[118]  I. Fidler,et al.  Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[119]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  Koichi Hattori,et al.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.

[121]  L. Ellis,et al.  Phase I study of recombinant human endostatin in patients with advanced solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  B. Curry,et al.  ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.

[123]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[124]  Eugene S. Kim,et al.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[125]  L. Ellis,et al.  Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. , 2002, European journal of cancer.

[126]  M. Kuwano,et al.  ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. , 2002, Cancer research.

[127]  L. Ellis,et al.  Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors , 2001, British Journal of Cancer.

[128]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[129]  G. Fontanini,et al.  Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[130]  S. Grimm,et al.  Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[131]  C. Chastang,et al.  Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  P. V. van Diest,et al.  Expression of growth factors, growth‐inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis , 1998, The Journal of pathology.

[133]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[134]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[135]  H. Verspaget,et al.  Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. , 1996, British Journal of Cancer.

[136]  Y. Okada,et al.  Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. , 1995, Cancer research.